Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies
Tallantyre et al.
The finding, in our words
This study validated a method combining quantitative dried blood spots with DNA methylation analysis to monitor B-cell counts remotely, achieving 100% sensitivity and specificity for a specific clinical threshold. This decentralised approach facilitates patient-centric therapeutic drug monitoring for anti-CD20 therapies by overcoming the logistical barriers of regular venous sampling.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
A quantitative dried blood spot method using only 10 µL of blood successfully quantified six azole antimycotics and showed samples were stable under conditions simulating postal mailing. A formula to convert dried spot results to plasma values was derived, though the authors note this is an in vitro validation and clinical studies are required for translation to patient care.
Deprez et al. validated LC‑MS/MS methods for four immunosuppressants and creatinine from a single 10 μL quantitative dried blood spot. With biases under 10 % and CVs below 8 %, the approach enables accurate patient‑centric therapeutic drug monitoring from capillary blood at home, mitigating the haematocrit effect through volumetric collection.
A review of VAMS and DBS microsampling for TDM of therapeutic monoclonal antibodies, adalimumab, infliximab and others, in inflammatory disease: a convenient, home-friendly alternative to venepuncture that can preserve analytical accuracy, subject to assay-specific validation.
A microfluidic DBS device using hydrophobic burst valves meters 5-15 μL blood accurately across 25-70% haematocrit and, in a therapeutic drug monitoring validation with adalimumab-spiked samples, achieves higher recovery than traditional DBS (86% versus 62%), supporting precise home or low-resource sampling.
The study found reasonable agreement between finger-prick dried blood spot CRP measurements and venous reference assays in 100 rheumatoid arthritis patients, particularly at low to mid-range CRP values, and showed that weekly self-collected DBS CRP monitoring improved flare detection specificity to 72.7% compared with 54.5% for minimal sampling, supporting decentralised microsampling for remote arthritis management.